問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

5163Cases

2024-10-25 - 2026-12-31

Phase I

Active
A Phase Ib/II Study to Evaluate HMBD-001 in Combination With Cetuximab, With or Without Docetaxel in Participants With Advanced Squamous Cell Carcinomas

  • Condition/Disease

    Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

  • Test Drug

    注射液劑 注射液劑 注射劑 注射液

Participate Sites
4Sites

Recruiting4Sites

2024-11-01 - 2027-04-30

Others

Active
Randomized, Multicenter, Multinational, Double-Blind Study to Compare the Pharmacokinetics, Efficacy, Safety and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) Versus Keytruda® in Combination With Chemotherapy for the Treatment of Patients With Advanced Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (BENITO Study)

  • Condition/Disease

    Non Squamous Non Small Cell Lung Cancer

  • Test Drug

    Injectable

Participate Sites
9Sites

Recruiting9Sites

2024-11-01 - 2028-12-31

Phase II

A Multinational Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety and Efficacy of Mirivadelgat, an Aldehyde Dehydrogenase 2 Activator, in Patients With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

  • Condition/Disease

    Group 3 Pulmonary Hypertension

  • Test Drug

    膠囊劑

Participate Sites
9Sites

Recruiting9Sites

2024-11-01 - 2029-08-31

Phase III

AndroMETa-CRC-064: An Open Label, Randomized, Controlled, Global Phase 3 Study Comparing Telisotuzumab Adizutecan (ABBV-400) Monotherapy to LONSURF (Trifluridine and Tipiracil) Plus Bevacizumab in Subjects With Refractory Metastatic Colorectal Cancer Expressing c-Met Protein Level Above a Defined Cutoff

  • Condition/Disease

    Metastatic Colorectal Cancer

  • Test Drug

    N/A

Participate Sites
10Sites

Recruiting10Sites

2024-11-01 - 2031-09-30

Phase III

Active
A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF PF-06821497 (MEVROMETOSTAT) WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MEVPRO-2)

  • Condition/Disease

    Metastatic Castration-Resistant Prostate Cancer

  • Test Drug

    Tablets Soft Capsules

Participate Sites
5Sites

Recruiting5Sites

2024-11-27 - 2028-05-29

Phase III

Active
A Phase III, Open-label, Sponsor-blind, Randomized Study of Dato-DXd With or Without Osimertinib Versus Platinum-based Doublet Chemotherapy for Participants With EGFR-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Has Progressed on Prior Osimertinib Treatment (TROPION-Lung15)

  • Condition/Disease

    Metastatic Non-small Cell Lung Cancer

  • Test Drug

    N/A 膜衣錠

Participate Sites
10Sites

Recruiting10Sites

2024-12-01 - 2025-11-30

Phase III

Completed
A Phase 3, Randomized, Observer-Blind, Active-Control Study to Evaluate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adults ≥50 Years of Age

  • Condition/Disease

    COVID-19、Influenza

  • Test Drug

    Suspension Injection

Participate Sites
8Sites

Recruiting8Sites

2024-12-01 - 2028-01-31

Phase III

Active
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Preventive Treatment of Menstrual Migraine

  • Condition/Disease

    Menstrual Migraine (MM)

  • Test Drug

    N/A

Participate Sites
5Sites

Recruiting5Sites

2024-12-26 - 2028-10-20

Active
A Phase 3, Open-Label, Randomized, Multinational Study to Investigate the Anti-tumor Efficacy of Golidocitinib Versus Investigator's Choice in Adult Patients With Relapsed/Refractory Peripheral T-cell Lymphoma

  • Condition/Disease

    Peripheral T-cell Lymphoma

  • Test Drug

    膠囊劑 注射用凍晶粉末 注射劑 錠劑

Participate Sites
8Sites

Recruiting8Sites

2020-08-01 - 2022-07-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

1 2 3 4 5 517
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB